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Abstract
Background: Bac7 is a proline-rich peptide with a potent in vitro antimicrobial activity against Gram-negative bacteria. 
Here we investigated its activity in biological fluids and in vivo using a mouse model of S. typhimurium infection.
Results: The efficacy of the active 1-35 fragment of Bac7 was assayed in serum and plasma, and its stability in biological 
fluids analyzed by Western blot and mass spectrometry. The ability of the peptide to protect mice against Salmonella 
was assayed in a typhoid fever model of infection by determination of survival rates and bacterial load in liver and 
spleen of infected animals. In addition, the peptide's biodistribution was evaluated by using time-domain optical 
imaging. Bac7(1-35) retained a substantial in vivo activity showing a very low toxicity. The peptide increased 
significantly the number of survivors and the mean survival times of treated mice reducing the bacterial load in their 
organs despite its rapid clearance.
Conclusions: Our results provide a first indication for a potential development of Bac7-based drugs in the treatment of 
salmonellosis and, eventually, other Gram-negative infections. The in vivo activity for this peptide might be substantially 
enhanced by decreasing its excretion rate or modifying the treatment schedule.
Background
The spread of multi-resistant bacterial pathogens poses a
serious threat to the global society in light of commonly
appearing hospital- and community-acquired drug-resis-
tant infections. It is therefore urgent to search for new
potent antimicrobial agents coping with arising pathogen
invasion and, at the same time, minimising the probabil-
ity of resistance induction in bacteria.
Antimicrobial peptides (AMPs) are widely recognized
as promising alternatives to the currently used antibiotics
and fungicides [1,2]. AMPs are widespread in living
organisms and constitute an important component of
innate immunity to microbial infections [3]. In mammals,
they are produced by granulocytes, macrophages and
most epithelial cells [4,5]. Amino-acid sequences of the
vast majority of AMPs share cationic and amphipathic
properties that allow their insertion into lipid bilayers and
can lead to alteration of biological membrane functions
[6]. Initial characterization studies linked these proper-
ties to antimicrobial killing activity. However, further data
indicated that this is not the only mode of action and that
more subtle mechanisms might mediate the interaction
with, and effect on target microbes, as well as the speci-
ficity and toxicity of peptides.
The proline-rich peptides (PRPs) are a distinctive group
of AMPs, isolated in different animal sources, which dis-
play an unusually high content of proline and arginine
residues in their sequences [7,8]. These peptides show a
spectrum of activity limited to Gram-negative bacteria
and appear to have a stereospecific mode of action medi-
ated by the internalization of the peptides into the cyto-
plasm without extensive membrane damaging effects [7].
Bac7 is a linear, 60-residue proline-rich peptide of
bovine origin corresponding to the C-terminal antimi-
crobial domain of a specific protein precursor of catheli-
cidin family [9]. Previous studies demonstrated that Bac7,
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and its C-terminal truncated form Bac7(1-35), have a
potent in vitro activity against many Gram-negative bac-
teria including Enterobacteriaceae, particularly Salmo-
nella spp., and the genera Pseudomonas, Acinetobacter,
and  Sinorhizobium  [10-12], while it is inactive against
most of the Gram-positive bacteria. Bac7(1-35) is also
active against multi-resistant clinical isolates [10] and is
able to neutralize endotoxin in experimental rat models
of Gram-negative septic shock [13]. In contrast to most
AMPs, this peptide is not toxic to mammalian cells at
concentrations well above those effective against
microbes [13,14]. In this respect, Bac7(1-35) is internal-
ized into eukaryotic cells through a pinocytic process
[14,15], but enters bacterial cells through a mechanism
mediated by the membrane protein SbmA/BacA [12,16].
These features suggest that Bac7 and its fragments might
be used in vivo without being toxic to the host and be
effective also against intracellular pathogens.
Despite the high potential of many AMPs as antimicro-
bial agents [17], in most cases, their residual toxicity
towards host cells and their rapid degradation and/or
inhibition by components of biological fluids represent a
real obstacle to their development as therapeutic mole-
cules [18,19].
In this study we investigated the in vitro activity of
Bac7(1-35) in a more physiological context, such as in
murine serum and plasma, and the in vivo potential in a
murine infection model of typhoid fever. Results indicate
that the peptide remains substantially active at the site of
infection and reduces significantly the mortality of
infected animals despite its rapid clearance.
Results and Discussion
Antibacterial activity of Bac7(1-35) in serum or plasma
Previous results showed that Bac7(1-35) has a potent in
vitro activity against Gram-negative bacteria [10]. Before
testing whether this peptide can also be active in vivo, we
assayed its antibacterial activity in vitro in the presence of
body fluid components. When killing kinetics assays were
performed in the presence of 66% murine plasma or
serum, the activity of Bac7(1-35) towards Salmonella
enterica serovar Typhimurium was reduced although still
detectable (Figure 1). In particular, after 1h-incubation
with serum or plasma, Bac7(1-35) (10 μM) reduced the
number of CFU by 0.5-1 log vs 2.5 log detected in the
absence of these biological fluids. To obtain a comparable
reduction of CFU without the presence of plasma/serum,
1 μM peptide should be used. At longer incubation times,
the activity of the proline-rich peptide seemed further
inhibited, especially by murine serum (Figure 1). We also
assayed the effects of serum albumin, the most abundant
protein in blood, on the peptide activity. In contrast to
what observed for other AMPs [19], the bactericidal
activity of Bac7(1-35) did not change upon addition of 40
mg/mL BSA, a concentration corresponding to that pres-
ent in the blood (data not shown).
Stability of Bac7(1-35) in serum and plasma
Inhibition of the peptide due to enzymatic degradation by
blood proteases was taken into account to explain the
reduced activity of Bac7(1-35) in biological fluids. The
stability of Bac7(1-35) was therefore evaluated by incu-
bating the peptide up to 24 h with murine plasma or
serum followed by Western blot analysis. Immunodetec-
tion indicated a slow and progressive reduction of the
band corresponding to intact Bac7(1-35), which disap-
peared after 24 h-incubation in serum (Figure 2A). The
degradation of Bac7(1-35) in plasma was slower (Figure
2A), suggesting that the activation of proteases of the
coagulation cascade in serum may contribute to the faster
peptide degradation in this medium. LC-MS analysis
indicated that the amount of intact Bac7(1-35) in murine
serum decreases by 10% after 1 h of incubation and that
the peptide was almost completely degraded after 8 h
(Figure 2B and 2C). The degradation process is slower in
plasma than in serum, (Figure 2B and 2C), confirming the
result observed in the Western blot analysis, while in PBS
alone, no peptide degradation was observed even after
several days of incubation at 37°C.
No fragments of Bac7(1-35) were detected by LC-MS
analysis. This may due to generation of hydrophilic frag-
ments of a few residues by responsible protease(s), which
are not detectable by either anti-Bac7 antibodies or LC-
MS. Enzymes such as trypsin-like serine proteases, which
Figure 1 Antimicrobial activity of Bac7(1-35) in the presence of 
biological fluids. Kinetics of the bactericidal activity of 10 μM Bac7(1-
35) against S. enterica ATCC 14028 in the absence (filled squares) or in 
the presence of 66% murine serum (filled circles), or 66% murine plas-
ma (filled triangles). Bacterial growth without peptide is indicated by 
empty symbols. Results represent the mean ± SD of three indepen-
dent determinations performed in triplicate.
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may cleave at the many Arg residues present in the
sequence of Bac7(1-35), might have this effect. However,
these results clearly indicate that the peptide should be
quite stable in blood and its degradation occurs only after
several hours, suggesting that the decreased activity of
Bac7(1-35) is only in part due to its degradation.
In vivo toxicity
As a first step to evaluate the therapeutic potential of
Bac7(1-35), its in vivo toxicity was determined in Balb/c
and CBA/Ca mice after injection via i.p. of increasing sin-
gle peptide doses. No apparent toxic effect was observed
when the peptide was administered i.p. up to 75 mg/kg,
but the mice receiving the highest peptide dose (150 mg/
kg) died 3 days post injection. This result confirms that
Bac7(1-35) is much less toxic than other cathelicidin-
derived peptides such as those belonging to the α-helical
group [20] and, in this respect, it behaves similarly to
insect proline-rich AMPs. For example, pyrrhocoricin
protected mice against E. coli infection, and showed no
toxicity up to the maximal applied dose i.v. of 50 mg/kg.
Drosocin is completely devoid of toxicity to healthy ani-
mals when used via i.v. at 100 mg/kg [8]. On the contrary,
lytic peptides such as BMAP-27 and -28 are toxic via i.p.
already at 10-15 mg/kg [20].
In vivo Bac7(1-35) activity in a mouse model of typhoid 
fever
The potential of Bac7(1-35) to protect mice from a bacte-
rial challenge was tested by a mouse model of Salmonella
infection. Infected mice develop a systemic disease char-
acterized by rapid bacterial multiplication in the liver and
spleen that resembles typhoid fever caused by Salmonella
serovar Typhi in humans [21]. Cell-mediated immunity
and macrophage activity play a key role in defence against
murine salmonellosis, and it has been shown that these
immune responses are lacking in Balb/c mice [22,23] so
that also the antibiotic ciprofloxacin failed to prevent
fatal S. typhimurium disease in this mouse strain [22]. For
this reason, we preferred to use CBA/Ca mice that show a
lower susceptibility to Salmonella infection [22] to study
the antimicrobial properties of Bac7(1-35). Nevertheless,
an acute infection may be induced by i.p. injection of less
than a hundred of CFU/mouse. Male CBA/Ca mice were
infected via i.p. with a lethal dose of S. typhimurium
ATCC 14028 (1 × 102 CFU/mouse), followed by i.p. injec-
tion of peptide at 30 mg/kg. The number of survivors was
monitored for 60 days and compared to that of control
mice that only received the lethal bacterial challenge. The
survival curves of untreated and peptide-treated mice are
significantly different (p = 0.01); the mean survival time
of control mice was 10 days, while the treatment of
infected mice with Bac7(1-35) increased the mean sur-
vival time to 24.5 days. It is worth noting that 36% of the
Figure 2 Bac7(1-35) stability in blood fractions. (A) Western blot 
analysis of Bac7(1-35) incubated for different times at 37°C in 25% mu-
rine serum or plasma. Lane 1: 0.5 μg Bac7(1-35); lanes 2-6: Bac 7(1-35) 
after incubation with murine serum or plasma for respectively 0, 1, 4, 8, 
24 hrs; lane 7: serum or plasma alone. (B) MC-LC chromatograms of 
Bac7(1-35) incubated at 37°C in 25% murine serum or plasma. (C) The 
percentages of Bac7(1-35) with respect to the t0 control were calculat-
ed following LC-MS analysis (see section Methods for further details) 
after incubation of the peptide with murine serum (filled squares) or 
plasma (filled triangles) for different times.
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infected mice treated with Bac7(1-35) were completely
cured with respect to 0% survival for untreated animals (p
= 0.04) (Figure 3A).
In parallel to survival experiments, a group of mice was
also analyzed for bacterial load at 3 days post-inoculation,
when the infected animals did not show any visible sign
of disease. Viable bacterial cells were counted in murine
liver and spleen of infected mice and results are reported
in Figure 3B. The number of viable bacterial cells in liver
and spleen homogenates decreased significantly in the
animals treated with the peptide at 30 mg/kg, despite a
remarkable variability in each group. In 1/3 of the animals
bacteria were undetectable in both the spleen and liver.
T h i s  r e s u l t  i s  i n  k e e p i n g  w i t h  t h e  p e r c e n t a g e  o f  m i c e
cured extrapolated by the survival curve (Figure 3A).
Given that i.p. injection of as few as 100 salmonellae is
lethal for mice, the increased survival times and the erad-
ication of the infection in 1/3 of the peptide-treated ani-
mals is a promising result. In addition, the protective role
showed by Bac7(1-35) suggests that the peptide may exert
its bactericidal action also in infected cells, since S. typh-
imurium is an intracellular pathogen and Bac7(1-35) is
able to penetrate host cells [14,15].
In vivo Time-Domain Optical Imaging
Following the results with the mouse model of infection,
we investigated the in vivo biodistribution of Bac7(1-35)
by using a time-domain optical imaging instrument [24]
and a derivative of Bac7(1-35), fluorescently labelled with
the dye Alexa680, showing an antimicrobial activity com-
parable to that of the unlabelled peptide (data not
shown).
The Bac7(1-35)-Alexa680 peptide shows a fast elimina-
tion kinetics after i.p. injection, characterized by a spe-
cific fluorescence intensity signal in the kidney first and
then in the bladder. The compound reaches the kidney
and the bladder in respectively 1 and 3 hours after the
injection. The in vivo and  ex vivo analyses performed
after 24 h confirm that the compound has been totally
excreted (Figure 4). These results suggest that the labelled
compound does not accumulate in any particular organ
except those involved in the elimination processes, kid-
ney and bladder, which result completely free of Bac7(1-
35)-Alexa680 one day after injection.
It is well known that mice eliminate drugs thought kid-
ney much more quickly than humans [25]. As no nefro-
toxic compounds causing renal dysfunction were used to
alter pharmacokinetic parameters [25], the very rapid
clearance of the peptide may likely have limited its activ-
ity against pathogens after injection in the animals. In the
light of this observation, the antibiotic activity of Bac7(1-
35) may be improved in the future by slowing the kinetics
of its renal excretion.
Conclusions
In conclusion, with this study we have shown that
Bac7(1-35) may exert antibacterial activity also in vivo, in
a mouse model of infection resembling typhoid fever in
humans. This model is particularly challenging in mice
due to the extremely low lethal dose of S. typhimurium.
Intraperitoneal injection of Bac7(1-35) at 30 mg/Kg
increased significantly the survival rate of infected mice
and the mean survival times suggesting that it inactivates
most of the inoculated bacteria in spite of a partial inhibi-
tion due to unknown blood components and a very fast
renal excretion rate.
Figure 3 In vivo activity of Bac7(1-35). Survival curves (A) and viable 
bacterial counts in liver and spleen homogenates (B) of mice infected 
with S. enterica after treatment via i.p. with Bac7(1-35) are shown. CBA/
Ca mice were infected via i.p. with S. enterica ATCC 14028 (102 CFU/
mouse) and Bac7(1-35) at 30 mg/kg was immediately injected via i.p. 
after bacterial challenge (dotted line). Control mice were given 0.2 ml 
of PBS (continuous line). Mice were monitored for survival over a 60-
day period after infection. *p < 0.05 treated vs untreated mice. Three 
days after bacterial infection, untreated (squares) and peptide-treated 
(triangles) mice were killed, and liver (full symbols) and spleen (empty 
symbols) homogenates were prepared as described in section Meth-
ods. Results are expressed as number of CFU/g organ; bars represent 
the mean value for each group.
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Figure 4 Biodistribution of Bac7(1-35)-Alexa680 in healthy mice after i.p. injection. (A) The animal was placed in prone position, fluorescence 
emission in regions of interest encompassing the kidneys were acquired at indicated times post-injection and normalized. (B) The animal was placed 
in supine position, fluorescence emission in regions of interest encompassing the thorax and abdomen was acquired at indicated times post-injection 
and normalized. (C) Ex vivo images of organs at 5 hours after i.p. injection. Imaging of the organs was performed immediately after sacrifice: laser power 
and integration time were optimized while keeping constant scan step to compare fluorescence intensities after normalization. The images are rep-
resentative of two independent experiments with comparable results.
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In the light of these observations, the results here
reported provide encouraging evidence for a future
development of a Bac7-based drug in the treatment of
Gram-negative infections. Its in vivo efficacy might be
improved by decreasing its clearance rate, for instance by
conjugation of the peptide with a drug delivery system.
Moreover, its effectiveness can also be improved by
changing the treatment regimen, for example with
repeated dosing. These studies are currently in progress.
Methods
Peptide synthesis and labelling
The N-terminal fragment 1-35 of Bac7 was synthesized,
purified and stored as described [11]. Bac7(1-35) was flu-
orescently-labelled via linkage of the thiol-reactive dye
ALEXA FLUOR® 680 C2-maleimide (Invitrogen, Carlsbad,
CA) to a specifically added C-terminal cysteine residue.
Briefly, the fluorophore ALEXA FLUOR® 680 (1 mg) was
dissolved in 100 μL DMSO, and added drop wise to 30
mL Na-phosphate buffer 10 mM, pH 7, under nitrogen
bubbling in the dark. Four mg of Bac7(1-35)-Cys were
dissolved in this solution; after 1 h incubation at room
temperature with stirring, a new aliquot of peptide (4 mg)
was added and the solution was left overnight at 4°C. At
the end of the incubation time, an excess of cysteine (10
mg) was added in this solution to scavenge the excess of
thiol-reactive reagent. The solution was left with stirring
for 1-2 h and the labelled peptide was purified by RP-
HPLC.
Antibacterial activity in serum and plasma
Murine plasma obtained using 2% (v/v) Na-citrate as an
anticoagulant, and serum were prepared and stored at -
20°C until use. The bactericidal activity of Bac7(1-35)
against Salmonella enterica serovar Typhimurium ATCC
14028 was determined by a killing kinetics assay [11].
Mid-logarithmic phase S. enterica cultures were diluted
in murine serum or plasma (66% v/v final concentration)
or BSA (40 mg/mL) (Sigma) to give approximately 1 × 106
cells/ml, and incubated with 10 μM Bac7(1-35) in a shak-
ing water bath at 37°C for different times. Samples were
withdrawn, diluted and plated to allow colony counts
[11].
Peptide stability in biological fluids
To test the peptide stability in biological fluids, 120 μg of
Bac7(1-35) were incubated in 200 μL of PBS containing
25% (v/v) m urine serum or plasma a t 37°C, or in PBS
alone. At different times, aliquots of samples were diluted
1:5 in sample buffer (12% SDS, 6% dithiothreitol, 40%
glycerol, 0.05% bromophenol blue, 150 mM Tris-HCl, pH
7), incubated for 15 min at 60°C and analyzed on a 16%
Tricine/SDS gel. Proteins were then blotted onto nitrocel-
lulose membrane (Whatman), and incubated overnight
with shaking at 4°C in 40 mM Tris-HCl, pH 7.5, 5% non-
fat milk, 0.05% Tween 20, 200 mM NaCl (blocking solu-
tion). Samples were incubated for 90 min with 1:1000
rabbit anti-Bac7(1-35) IgG, diluted in blocking solution,
followed by a HRP-conjugated anti-rabbit IgG (Sigma-
Aldrich). The ECL detection system (GE Healthcare) was
used to develop the Western blots.
LC-MS analysis
Bac7(1-35) peptide (50 μg) was incubated in 250 μL of
PBS containing 25% (v/v) of murine serum or plasma at
37°C. At different time intervals (0, 1, 2, 4, 8 and 24 h), ali-
quots of 25 μL (corresponding to 5 μg of peptide) were
added to 65 μL of cold 0.5% (v/v) TFA in H2O, kept on ice
for 5 min and than centrifuged at 10.000 × g for 5 min.
The LC-MS analysis of supernatants were carried out as
described [26], using a standard curve to calculate the
peptide concentration.
Animals
Male Balb/c and CBA/Ca mice of approximately 20 g and
6 weeks of age were obtained from Harlan Laboratories
(Udine, Italy) and maintained under pathogen-free condi-
tions. All the experimental procedures were performed
according to the guidelines of the European (86/609/
EEC) and the Italian (D.L.116/92 and subsequent
addenda) laws and approved by the Italian Ministry of
University and Research as well as by the Animal Experi-
mentation Committee of the University Animal House.
In vivo studies
The  in vivo toxicity of Bac7(1-35) was investigated by
injecting mice via i.p. with increasing amounts of the
peptide dissolved in apyrogen PBS (0.2 ml per mouse).
The controls received the vehicle alone. Animal behavior
and survival were monitored over a 14-day period.
Inocula containing 102 CFU/mouse of S. enterica ATCC
14028, expected to result in 90-100% mortality in 4-6
days for Balb/c [27] and 10-18 days for CBA/Ca, were
prepared by diluting log-phase bacterial cultures in sterile
PBS. Ten mice were infected intraperitoneally and moni-
tored for survival over a 60-day period after infection.
Test peptide (30 mg/kg) was injected via i.p. after bacte-
rial challenge. The choice of dose was based on prelimi-
nary data obtained with lower doses (data not shown) and
on results reported in the literature for structurally simi-
lar peptides. Control mice were given 0.2 ml of PBS. The
experiment was repeated two times and comparable
results were obtained. The analysis of survival curves was
conducted using the Kaplan-Meyer method and succes-
sive statistical evaluation by the Logrank test. Signifi-
cance of percentage differences among groups was
assessed by using the Fisher exact test. Values of p < 0.05
were considered statistically significant.Benincasa et al. BMC Microbiology 2010, 10:178
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Viable colony counts in murine liver and spleen 
homogenates
Three days after bacterial infection, a group of 3
untreated and 3 peptide-treated mice were killed by cer-
vical dislocation, and liver and spleen were removed. The
organs were weighed, homogenized separately and dis-
solved in PBS. Suitable dilutions of 50 μL of the homoge-
nate in PBS were plated in duplicate on Mueller-Hinton
agar (Difco). The plates were then incubated at 37°C
overnight to allow colony counts. Results are expressed as
number of CFU/g of organ. This assay was repeated two
fold.
Mice preparation and treatment for in vivo Time-Domain 
Optical Imaging
The day before the treatment, healthy CBA mice were
anesthetized by an intramuscular injection of a diluted
mixture (1:5 in PBS) composed by 0.4 mL Zoletil 100 and
0.25 mL Rompun 2% (3 μL/g body weight), and shaved in
the regions of interest to avoid laser scattering caused by
hair. The following day, mice were anesthetized using a
gaseous anaesthesia system (2Biological Instruments,
Italy), based on isoflurane mixed to oxygen and nitrogen
protoxide. Anaesthesia was first induced with 2% isoflu-
rane in a pre-anaesthesia chamber and then the animals
were placed inside the eXplore Optix in the presence of
1% isoflurane. Two mice were then injected intraperito-
neally with 36.6 μg/mouse of Bac7(1-35)-Alexa680, corre-
sponding to 6.9 nmol ALEXA FLUOR®  680, one
monitored in the abdominal region and the other in the
renal region for 24 hours. A blank image was acquired
before treatment of each animal and this was subtracted
to the images of the treated animal. Experiment was
repeated two times.
The small-animal time-domain eXplore Optix preclini-
cal imager (GE Healthcare) was used in this study. In all
imaging experiments, a 670 nm pulsed laser diode with a
repetition frequency of 80 MHz and a time resolution of
12 ps light pulse was used for excitation. The fluores-
cence emission at 700 nm was collected and detected
through a fast photomultiplier tube and a highly sensitive
time-correlated single-photon counting system. Two-
dimensional scanning regions of interest (ROI) were
selected and the laser power, integration time and scan
step were optimized according to the signal emitted. The
data were recorded as temporal point-spread functions,
and the images were reconstructed as fluorescence inten-
sity and lifetime.
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